Immunovant (IMVT) Competitors

Immunovant (NASDAQ:IMVT) and Viatris (NASDAQ:VTRS) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability.

Which has better earnings & valuation, IMVT or VTRS?

Viatris has higher revenue and earnings than Immunovant. Viatris is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$259.34M	-$2.62	-5.90
Viatris	$14.74B	0.61	$54.70M	-$0.53	-14.11

Does the MarketBeat Community prefer IMVT or VTRS?

Immunovant received 109 more outperform votes than Viatris when rated by MarketBeat users. Likewise, 78.11% of users gave Immunovant an outperform vote while only 34.85% of users gave Viatris an outperform vote.

Company	Underperform	Outperform
Immunovant	Outperform Votes 132 78.11%	Underperform Votes 37 21.89%
Viatris	Outperform Votes 23 34.85%	Underperform Votes 43 65.15%

Do insiders & institutionals believe in IMVT or VTRS?

47.1% of Immunovant shares are held by institutional investors. Comparatively, 79.9% of Viatris shares are held by institutional investors. 5.9% of Immunovant shares are held by company insiders. Comparatively, 0.1% of Viatris shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Do analysts recommend IMVT or VTRS?

Immunovant presently has a consensus target price of $41.00, indicating a potential upside of 165.03%. Viatris has a consensus target price of $10.50, indicating a potential upside of 40.37%. Given Immunovant's stronger consensus rating and higher possible upside, research analysts plainly believe Immunovant is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	3.00
Viatris	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

Which has more risk & volatility, IMVT or VTRS?

Immunovant has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500. Comparatively, Viatris has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500.

Does the media favor IMVT or VTRS?

In the previous week, Viatris had 41 more articles in the media than Immunovant. MarketBeat recorded 55 mentions for Viatris and 14 mentions for Immunovant. Immunovant's average media sentiment score of 1.16 beat Viatris' score of 0.02 indicating that Immunovant is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	10 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Viatris	3 Very Positive mention(s)	7 Positive mention(s)	36 Neutral mention(s)	4 Negative mention(s)	4 Very Negative mention(s)	Neutral

Is IMVT or VTRS more profitable?

Immunovant has a net margin of 0.00% compared to Viatris' net margin of -5.87%. Viatris' return on equity of 16.46% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-77.94%	-69.82%
Viatris	-5.87%	16.46%	7.09%

Summary

Immunovant beats Viatris on 10 of the 18 factors compared between the two stocks.